Abstract
Although the great part of patients with colorectal cancer undergoes curative surgery, 50% of them eventually die of the disease. Early detection of recurrences must then be regarded as a major effort in order to improve post surgical survival. Recently, the determination of tumor markers with the aim of obtaining earlier detection of recurrences and reliable information that may guide the decision whether performing second look surgery has been proposed in clinical protocols as a complementary tool to clinical and instrumental investigations. Despite the quite promising data on the value of increased serum levels of some tumor markers, mainly the carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA) and CA 19-9, in predicting tumor reappearance, the real gain in terms of survival remains to be defined. This article reviews the current available data on the clinical role and the usefulness of biochemical monitoring in this tumor type, identifying and discussing the key issues of a rational approach for the use of tumor markers in colorectal cancer patient follow-up programs.
| Original language | English |
|---|---|
| Pages (from-to) | 112-116 |
| Number of pages | 5 |
| Journal | European Journal of Laboratory Medicine |
| Volume | 4 |
| Issue number | 2 |
| Publication status | Published - 1996 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Clinical usefulness of biochemical monitoring in colorectal cancer. / Plebani, M.; Delle Fave, G.; Fiocca, R.; Saggioro, A.; Savarino, V.; Stanghellini, V.
In: European Journal of Laboratory Medicine, Vol. 4, No. 2, 1996, p. 112-116.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Clinical usefulness of biochemical monitoring in colorectal cancer
AU - Plebani, M.
AU - Delle Fave, G.
AU - Fiocca, R.
AU - Saggioro, A.
AU - Savarino, V.
AU - Stanghellini, V.
PY - 1996
Y1 - 1996
N2 - Although the great part of patients with colorectal cancer undergoes curative surgery, 50% of them eventually die of the disease. Early detection of recurrences must then be regarded as a major effort in order to improve post surgical survival. Recently, the determination of tumor markers with the aim of obtaining earlier detection of recurrences and reliable information that may guide the decision whether performing second look surgery has been proposed in clinical protocols as a complementary tool to clinical and instrumental investigations. Despite the quite promising data on the value of increased serum levels of some tumor markers, mainly the carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA) and CA 19-9, in predicting tumor reappearance, the real gain in terms of survival remains to be defined. This article reviews the current available data on the clinical role and the usefulness of biochemical monitoring in this tumor type, identifying and discussing the key issues of a rational approach for the use of tumor markers in colorectal cancer patient follow-up programs.
AB - Although the great part of patients with colorectal cancer undergoes curative surgery, 50% of them eventually die of the disease. Early detection of recurrences must then be regarded as a major effort in order to improve post surgical survival. Recently, the determination of tumor markers with the aim of obtaining earlier detection of recurrences and reliable information that may guide the decision whether performing second look surgery has been proposed in clinical protocols as a complementary tool to clinical and instrumental investigations. Despite the quite promising data on the value of increased serum levels of some tumor markers, mainly the carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA) and CA 19-9, in predicting tumor reappearance, the real gain in terms of survival remains to be defined. This article reviews the current available data on the clinical role and the usefulness of biochemical monitoring in this tumor type, identifying and discussing the key issues of a rational approach for the use of tumor markers in colorectal cancer patient follow-up programs.
UR - http://www.scopus.com/inward/record.url?scp=0030445631&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030445631&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0030445631
VL - 4
SP - 112
EP - 116
JO - European Journal of Laboratory Medicine
JF - European Journal of Laboratory Medicine
SN - 1122-8652
IS - 2
ER -